Loading clinical trials...
Loading clinical trials...
Non-randomised, Open Label, Multi-centre Phase II Study to Assess the Efficacy and Safety of SB-497115-GR in Thrombocytopenic Subjects With Chronic Hepatitis C and Compensated Liver Cirrhosis.
Conditions
Interventions
SB-497115-GR
Locations
16
Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Fukui, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Gunma, Japan
GSK Investigational Site
Hyōgo, Japan
Start Date
July 1, 2012
Primary Completion Date
May 1, 2014
Completion Date
November 1, 2014
Last Updated
March 1, 2016
NCT05870969
NCT03987503
NCT04382404
NCT01226797
NCT00062816
NCT04774107
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions